THE POTENTIAL APPLICATIONS OF QUANTUM COMPUTING IN PERSONALIZED MEDICINE TO DEVELOP TAILORED TREATMENT PLANS FOR INDIVIDUAL PATIENTS
Keywords:
Quantum Computing, Healthcare, Technology, Drug DiscoveryAbstract
To investigate possible future applications, this presentation will offer an overview of the status of quantum computing in the health industry. By significantly increasing the speed and precision of numerous operations including drug discovery, customized medicine, and medical imaging, quantum computing has the potential to change a broad variety of sectors, including healthcare. The numerous uses of quantum computing in the health sector are revealed, as well as the present level of research in this field, via a survey of the available literature on the subject. Although technology is still in its early phases of development, this study indicates that quantum computing has the potential to completely transform the healthcare industry. However, further research is required to properly comprehend the implications of quantum computing in healthcare. Artificial intelligence (AI) techniques are used in precision medicine to explore novel genotypes and phenotypes data. The main aims of precision medicine include early diagnosis, screening, and personalized treatment regime for a patient based on genetic-oriented features and characteristics. The main objective of this study was to review AI techniques and their effectiveness in neoplasm precision medicine.
References
Ü. Budak, Y. Guo, E. Tanyildizi, and A. Şengür, “Cascaded deep convolutional encoder-decoder neural networks for effi- cient liver tumor segmentation,” Medical Hypotheses., vol. 134, article 109431, 2022.
L. Meng, Q. Zhang, and S. Bu, “Two-stage liver and tumor seg- mentation algorithm based on convolutional neural network,” Diagnostics, vol. 11, no. 10, p. 1806, 2021.
L. Meng, Y. Tian, and S. Bu, “Liver tumor segmentation based on 3D convolutional neural network with dual scale,” Journal of Applied Clinical Medical Physics, vol. 21, no. 1, pp. 144– 157, 2022.
C. Turnbull, A. Sud, and R. S. Houlston, “Cancer genetics, pre-cision prevention and a call to action,” Nature Genetics, vol. 50, no. 9, pp. 1212–1218, 2018.
J. T. Loud and J. Murphy, “Cancer screening and early detec- tion in the 21st century,” in Seminars in oncology nursing, Else- vier, 2017.
T. Lu, X. Yang, Y. Huang et al., “Trends in the incidence, treat- ment, and survival of patients with lung cancer in the last four decades,” Cancer Management and Research, vol. Volume 11, pp. 943–953, 2019.
Z. Chen, L. Xu, W. Shi et al., “Trends of female and male breast cancer incidence at the global, regional, and national levels, 1990–2017,” Breast Cancer Research and Treatment, vol. 180, no. 2, pp. 481–490, 2022.
Collaboration GBoDC, “Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disabil- ity, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017,” JAMA Oncology, vol. 5, no. 12, pp. 1749– 1768, 2019.
A. Holzinger, “Trends in interactive knowledge discovery for personalized medicine: cognitive science meets machine learn- ing,” The IEEE Intelligent Informatics Bulletin, vol. 15, no. 1, pp. 6–14, 2014.
J. L. Vassy, B. R. Korf, and R. C. Green, “How to know when physicians are ready for genomic medicine,” Science Transla- tional Medicine, vol. 7, no. 287, 2015.
R. Hochstenbach, E. van Binsbergen, H. Schuring- Blom, Buijs, and H. K. P. van Amstel, “A survey of undetected, clinically relevant chromosome abnormalities when eplacing postnatal karyotyping by whole genome sequencing,” Euro- pean Journal of Medical Genetics, vol. 62, no. 9, article 103543, 2019.
O. Adir, M. Poley, G. Chen et al., “Integrating artificial intelli- gence and nanotechnology for precision cancer medicine,” Advanced Materials, vol. 32, no. 13, p. 1901989, 2022.
I. Kavakiotis, O. Tsave, A. Salifoglou, N. Maglaveras, I. Vlahavas, and I. Chouvarda, “Machine learning and data mining methods in diabetes research,” Computational and Structural Biotechnology Journal, vol. 15, pp. 104–116, 2017.
A. Qayyum, A. Lalande, and F. Meriaudeau, “Automatic seg- mentation of tumors and affected organs in the abdomen using a 3D hybrid model for computed tomography imaging,” Com- puters in Biology and Medicine, vol. 127, article 104097, 2022.
M. J. Page, D. Moher, P. M. Bossuyt et al., “PRISMA 2022 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews,” BMJ, vol. 372, 2021.
H. Polmann, F. L. Domingos, G. Melo et al., “Association between sleep bruxism and anxiety symptoms in adults: a sys- tematic review,” Journal of Oral Rehabilitation, vol. 46, no. 5, pp. 482–491, 2019.
D. M. Powers, “Evaluation: from precision, recall and F- measure to ROC, informedness, markedness and correlation,” 2022, https://arxiv.org/abs/201016061.
G. Xiao, S. Ma, J. Minna, and Y. Xie, “Adaptive prediction model in prospective molecular signature–based clinical stud- ies,” Clinical Cancer Research, vol. 20, no. 3, pp. 531– 539, 2014.
A. C. Kaushik, M. Li, A. Mehmood, X. Dai, and D.-Q. Wei, “ACPS: an accurate bioinformatics tool for precision- based anti-cancer peptide generation via omics data,” Chemical Biol- ogy And Drug Design, vol. 97, no. 2, pp. 372–382, 2021.
J.-F. Laplante and M. A. Akhloufi, “Predicting cancer types from miRNA stem-loops using deep learning,” in 2022 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC), Montreal, QC, Canada, 2022.
H. Yu, J. Yang, and J. Han, “Classifying large data sets using SVMs with hierarchical clusters,” in Proceedings of the ninth ACM SIGKDD international conference on Knowledge discov- ery and data mining, Washington, D.C, 2003.
T. Tang, S. Chen, M. Zhao, W. Huang, and J. Luo, “Very large- scale data classification based on K-means clustering and multi-kernel SVM,” Soft Computing, vol. 23, no. 11, pp. 3793–3801, 2019.
W.-J. Lin and J. J. Chen, “Class-imbalanced classifiers for high- dimensional data,” Briefings in Bioinformatics, vol. 14, no. 1, pp. 13–26, 2013.
T. N. Sainath, A. Mohamed, B. Kingsbury, and Ramabhadran, “Deep convolutional neural networks for LVCSR,” in 2013 IEEE international conference on acoustics, speech and signal processing, Vancouver, BC, Canada, 2013.
C. Sun, X. Tian, Z. Liu et al., “Radiomic analysis for pretreat- ment prediction of response to neoadjuvant chemotherapy in locally advanced cervical cancer: a multicentre study,” eBioMe- dicine, vol. 46, pp. 160–169, 2019.
M. K. Breitenstein, H. Liu, K. N. Maxwell, J. Pathak, and R. Zhang, “Electronic health record phenotypes for precision medicine: perspectives and caveats from treatment of breast cancer at a single institution,” Clinical and Translational Sci- ence, vol. 11, no. 1, pp. 85–92, 2018.
B. Chen, L. Zhong, D. Dong et al., “Computed tomography radiomic nomogram for preoperative prediction of Extrathyr- oidal extension in papillary thyroid carcinoma,” Frontiers in Oncology, vol. 9, p. 829, 2019.
Y. Shen, C. Wu, C. Liu, Y. Wu, and N. Xiong, “Oriented feature selection SVM applied to cancer prediction in precision med- icine,” IEEE Access, vol. 6, pp. 48510–48521, 2018.
T. Kempowsky-Hamon, C. Valle, M. Lacroix-Triki et al., “Fuzzy logic selection as a new reliable tool to identify molec- ular grade signatures in breast cancer – the INNODIAG study,” BMC Medical Genomics, vol. 8, no. 1, pp. 015–0077, 2015.
M. E. Maros, D. Capper, D. T. Jones et al., “Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data,” Nature Protocols, vol. 15, no. 2, pp. 479–512, 2022.
Y. Zhu, T. Brettin, Y. A. Evrard et al., “Ensemble transfer learn- ing for the prediction of anti-cancer drug response,” Scientific Reports, vol. 10, no. 1, pp. 1–11, 2022.
R. Sharma, “Breast cancer incidence, mortality and mortality- to-incidence ratio (MIR) are associated with human develop- ment, 1990–2016: evidence from global burden of disease study 2016,” Breast Cancer, vol. 26, no. 4, pp. 428–445, 2019.
C. Calabrese, N. R. Davidson, D. Demircioğlu et al., “Genomic basis for RNA alterations in cancer,” Nature, vol. 578, no. 7793, pp. 129–136, 2022.
K. Uhr, W. J. Prager-van der Smissen, A. A. Heine et al., “Micro- RNAs as possible indicators of drug sensitivity in breast cancer cell lines,” PloS One, vol. 14, no. 5, article e0216400, 2019.
D. B. Peckys, C. Quint, and N. Jonge, “Determining the effi- ciency of single molecule quantum dot labeling of HER2 in breast cancer cells,” Nano Letters, vol. 20, no. 11, pp. 7948– 7955, 2022.
G. Ferone, M. C. Lee, J. Sage, and A. Berns, “Cells of origin of lung cancers: lessons from mouse studies,” Genes & Develop- ment, vol. 34, no. 15-16, pp. 1017–1032, 2022.
A. S. Hauser, M. M. Attwood, M. Rask-Andersen, H. B. Schiöth, and D. E. Gloriam, “Trends in GPCR drug discovery: new agents, targets and indications,” Nature Reviews Drug Dis- covery, vol. 16, no. 12, pp. 829–842, 2017.
J. A. B. Iriart, “Precision medicine/personalized medicine: a critical analysis of movements in the transformation of bio- medicine in the early 21st century,” Cadernos de saúde publica, vol. 35, 2019.
E. A. Ashley, “Towards precision medicine,” Nature Reviews Genetics, vol. 17, no. 9, pp. 507–522, 2016.
E. D. Green and M. S. Guyer, “Charting a course for genomic medicine from base pairs to bedside,” Nature, vol. 470, no. 7333, pp. 204–213, 2011.
F. S. Collins and H. Varmus, “A new initiative on precision medicine,” New England Journal of Medicine, vol. 372, no. 9, pp. 793–795, 2015.
J. L. Fox, “Obama catapults patient-empowered precision medicine,” Nature Biotechnology, vol. 33, no. 4, p. 325, 2015.
D.-H. Le and V.-H. Pham, “Drug response prediction by glob- ally capturing drug and cell line information in a heteroge- neous network,” Journal of Molecular Biology, vol. 430, no. 18, pp. 2993–3004, 2018.
R. Gatta, M. Vallati, N. Dinapoli et al., “Towards a modular decision support system for radiomics: a case study on rectal cancer,” Artificial Intelligence in Medicine, vol. 96, pp. 145– 153, 2019.
H. Shimizu and K. I. Nakayama, “A 23 gene-based molecular prognostic score precisely predicts overall survival of breast cancer patients,” eBioMedicine, vol. 46, pp. 150–159, 2019.
C. L. Overby, E. B. Devine, P. Tarczy-Hornoch, and I. J. Kalet, “Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions,” Journal of the American Medical Infor- matics Association, vol. 19, no. 5, pp. 840– 850, 2012.
R. J. Urbanowicz, A. S. Andrew, M. R. Karagas, and J. H. Moore, “Role of genetic heterogeneity and epistasis in bladder cancer susceptibility and outcome: a learning classifier system approach,” Journal of the American Medical Informatics Asso- ciation, vol. 20, no. 4, pp. 603– 612, 2013.
M. Q. Ding, L. Chen, G. F. Cooper, J. D. Young, and X. Lu, “Precision oncology beyond targeted therapy: combining omics data with machine learning matches the majority of cancer cells to effective therapeutics,” Molecular Cancer Research, vol. 16, no. 2, pp. 269–278, 2018.
J. Diggans, S. Y. Kim, Z. Hu et al., Machine learning from con- cept to clinic: reliable detection of BRAF V600E DNA mutations in thyroid nodules using high-dimensional RNA expression data. Pacific Symposium on Biocomputing Co- Chairs, World Scientific, 2014.
V. Gligorijević, N. Malod-Dognin, and N. Pržulj, Patient-spe- cific data fusion for cancer stratification and personalised treat- ment. Biocomputing 2016: Proceedings of the Pacific Symposium, World Scientific, 2016.
E. Acar, A. Leblebici, B. E. Ellidokuz, Y. Başbınar, and G. Ç. Kaya, “Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study,” The British Journal of Radiol- ogy, vol. 92, no. 1101, p. 20190286, 2019.
A. M. Alaa, K. H. Moon, W. Hsu, and M. Van Der Schaar, “Confidentcare: a clinical decision support system for person- alized breast cancer screening,” IEEE Transactions on Multi- media, vol. 18, no. 10, pp. 1942– 1955, 2016.
A. Boucheham and M. Batouche, “Robust biomarker discovery for cancer diagnosis based on meta-ensemble feature selec- tion,” in 2014 Science and Information Conference, London, UK, 2014.
O. Nikolova, R. Moser, C. Kemp, M. Gönen, and A. A. Margolin, “Modeling gene-wise dependencies improves the identification of drug response biomarkers in cancer stud- ies,” Bioinformatics, vol. 33, no. 9, pp. 1362–1369, 2017.
X. He, L. Folkman, and K. Borgwardt, “Kernelized rank learn- ing for personalized drug recommendation,” Bioinformatics, vol. 34, no. 16, p. 2808, 2018.
P. Mobadersany, S. Yousefi, M. Amgad et al., “Predicting can- cer outcomes from histology and genomics using convolu- tional networks,” Proceedings of the National Academy of Sciences, vol. 115, no. 13, pp. E2970–E2979, 2018.
S. Fathiamini, A. M. Johnson, J. Zeng et al., “Automated iden- tification of molecular effects of drugs (AIMED),” Journal of the American Medical Informatics Association, vol. 23, no. 4, pp. 758–765, 2016.
K. Itahashi, S. Kondo, T. Kubo et al., “Evaluating clinical genome sequence analysis by Watson for genomics,” Frontiers in Medicine, vol. 5, p. 305, 2018.
F. Wang, B. Zhang, X. Wu et al., “Radiomic nomogram improves preoperative T category accuracy in locally advanced laryngeal carcinoma,” Frontiers in Oncology, vol. 9, p. 1064, 2019.
K. Graim, V. Friedl, K. E. Houlahan, and J. M. Stuart, PLATY- PUS: a multiple-view learning predictive framework for cancer drug sensitivity prediction. PSB, World Scientific, 2019.
L. K. Jones, F. Zou, A. Kheifets, K. Rybnikov, D. Berry, and A. C. Tan, “Confident predictability: identifying reliable gene expression patterns for individualized tumor classification using a local minimax kernel algorithm,” BMC Medical Geno- mics, vol. 4, no. 1, p. 10, 2011.
D.-C. Kim, J. Gao, X. Wang, and C.-R. Yang, “A framework for personalized medicine with reverse phase protein array and drug sensitivity,” in 2011 IEEE International Conference on Bioinformatics and Biomedicine, Atlanta, GA, USA, 2011.
S. Li, H. Han, D. Sui, A. Hao, and H. Qin, “A novel radioge- nomics framework for genomic and image feature correlation using deep learning,” in 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), Madrid, Spain, 2018.
P. Lin, D.-y. Wen, L. Chen et al., “A radiogenomics signature for predicting the clinical outcome of bladder urothelial carci- noma,” European Radiology, vol. 30, no. 1, pp. 547–557, 2022.
M. P. Menden, F. Iorio, M. Garnett et al., “Machine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical properties,” PLoS One, vol. 8, no. 4, article e61318, 2013.
H. Moon, H. Ahn, R. L. Kodell, S. Baek, C.-J. Lin, and J. J. Chen, “Ensemble methods for classification of patients for per- sonalized medicine with high-dimensional data,” Artificial Intelligence in Medicine, vol. 41, no. 3, pp. 197– 207, 2007.
A. Assawamakin, S. Prueksaaroon, S. Kulawonganunchai et al., “Biomarker selection and classification of “-omics” data using a two-step Bayes classification framework,” BioMed Research International, vol. 2013, 9 pages, 2013.
B. Majumder, U. Baraneedharan, S. Thiyagarajan et al., “Pre- dicting clinical response to anticancer drugs using an _ex vivo_ platform that captures tumour heterogeneity,” Nature Communications, vol. 6, no. 1, p. 6169, 2015.
M. Y. Sun, W. Zhou, X. Q. Qi et al., “Prediction of BAP1 expression in uveal melanoma using densely-connected deep classification networks,” Cancers, vol. 11, no. 10, p. 1579, 2019.
N. Potie, S. Giannoukakos, M. Hackenberg, and A. Fernandez, “On the Need of Interpretability for Biomedical Applications: Using Fuzzy Models for Lung Cancer Prediction with Liquid Biopsy,” in IEEE International Conference on Fuzzy Systems, New Orleans, LA, USA, 2019.
K. H. Yu, D. A. Levine, H. Zhang, D. W. Chan, Z. Zhang, and M. Snyder, “Predicting ovarian cancer Patients' clinical response to platinum-based chemotherapy by their tumor pro- teomic signatures,” Journal of Proteome Research, vol. 15, no. 8, pp. 2455–2465, 2016.
K. R. Kalari, J. P. Sinnwell, K. J. Thompson et al., “PANOPLY: omics-guided drug prioritization method tailored to an indi- vidual patient,” JCO Clinical Cancer Informatics, vol. 2, pp. 1–11, 2018.
M. I. Klein, D. F. Stern, and H. Zhao, “GRAPE: a pathway tem- plate method to characterize tissue-specific functionality from gene expression profiles,” BMC Bioinformatics, vol. 18, no. 1, pp. 017–1711, 2017.
Z. Dong, N. Zhang, C. Li et al., “Anticancer drug sensitivity prediction in cell lines from baseline gene expression through recursive feature selection,” BMC Cancer, vol. 15, no. 1, pp. 015–1492, 2015.
E.-M. Yasser, T.-Y. Hsieh, M. Shivakumar, D. Kim, and V. Honavar, “Min-redundancy and max-relevance multi- view feature selection for predicting ovarian cancer survival. using multi-omics data,” BMC Medical Genomics, vol. 11, no. 3, pp. 19–31, 2018.
Y. Chang, H. Park, H. J. Yang et al., “Cancer drug response profile scan (CDRscan): a deep learning model that predicts drug effectiveness from cancer genomic signature,” Scientific Reports, vol. 8, no. 1, pp. 018–27214,2018.
C. Huang, E. A. Clayton, L. V. Matyunina et al., “Machine learning predicts individual cancer patient responses to thera- peutic drugs with high accuracy,” Scientific Reports, vol. 8, no. 1, pp. 018–34753, 2018.
G. S. Ow and V. A. Kuznetsov, “Big genomics and clinical data analytics strategies for precision cancer prognosis,” Scientific Reports, vol. 6, no. 1, p. 36493, 2016.
J. Yu, Y. Hu, Y. Xu et al., “LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features,” BMC Cancer, vol. 19, no. 1,pp. 1–10, 2019.
L. Dercle, J. Ma, C. Xie et al., “Using a single abdominal com- puted tomography image to differentiate five contrast- enhancement phases: a machine-learning algorithm for radiomics-based precision medicine,” European Journal of Radiology, vol. 125, article 108850, 2022.
L. Zhang, D. Dong, W. Zhang et al., “A deep learning risk pre- diction model for overall survival in patients with gastric can- cer: a multicenter study,” Radiotherapy and Oncology, vol. 150,pp. 73–80, 2022.
R. Su, X. Liu, L. Wei, and Q. Zou, “Deep-Resp-Forest: a deep forest model to predict anti-cancer drug response,” Methods, vol. 166, pp. 91–102, 2019.
T. Mahmood, M. Owais, K. J. Noh et al., “Accurate segmenta- tion of nuclear regions with multi-organ histopathology images using artificial intelligence for cancer diagnosis in per- sonalized medicine,” Journal of Personalized Medicine, vol. 11, no. 6, p. 515, 2021.
V. Malik, Y. Kalakoti, and D. Sundar, “Deep learning assisted multi-omics integration for survival and drug- response pre- diction in breast cancer,” BMC Genomics, vol. 22, no. 1, pp. 1–11, 2021.
P. M. do Nascimento, I. G. Medeiros, R. M. Falcão, B. Stransky, and J. E. S. de Souza, “A decision tree to improve identification of pathogenic mutations in clinical practice,” BMC Medical Informatics and Decision Making, vol. 20, no. 1, pp. 1–11, 2022.
J. Choi, S. Park, and J. Ahn, “Refdnn: a reference drug based neural network for more accurate prediction of anticancer drug resistance,” Scientific Reports, vol. 10, no. 1, pp. 1–11, 2022.
K. Koras, D. Juraeva, J. Kreis, J. Mazur, E. Staub, and E. Szczurek, “Feature selection strategies for drug sensitivity prediction,” Scientific Reports, vol. 10, no. 1, pp. 1–12, 2022.
S. Luo, J. Xu, Z. Jiang et al., “Artificial intelligence-based col- laborative filtering method with ensemble learning for person- alized lung cancer medicine without genetic sequencing,” Pharmacological Research, vol. 160, article 105037, 2022.
H. Sharifi-Noghabi, S. Peng, O. Zolotareva, C. C. Collins, and M. Ester, “AITL: Adversarial inductive transfer learning with input and output space adaptation for pharmacogenomics,” Bioinformatics, vol. 36, Supplement_1, pp. i380–i388, 2022.
O. Bazgir, S. Ghosh, and R. Pal, “Investigation of REFINED CNN ensemble learning for anti-cancer drug sensitivity pre- diction,” Bioinformatics, vol. 37, Supplement_1, pp. i42–i50, 2021.
G. Woo, M. Fernandez, M. Hsing, N. A. Lack, A. D. Cavga, and A. Cherkasov, “DeepCOP: deep learning-based approach to predict gene regulating effects of small molecules,” Bioinfor- matics, vol. 36, no. 3, pp. 813–818, 2022.
M. A. Jacobs, C. B. Umbricht, V. S. Parekh et al., “Integrated multiparametric radiomics and informatics system for charac- terizing breast tumor characteristics with the OncotypeDX gene assay,” Cancers, vol. 12, no. 10, p. 2772, 2022.
Q. Li, J. Huang, H. Zhu, and Q. Liu, “Prediction of cancer drug effectiveness based on multi-fusion deep learning model,” in 2022 10th Annual Computing and Communication Workshop and Conference (CCWC), Las Vegas, NV, USA, 2022.
Q. Liu, L. J. Muglia, and L. F. Huang, “Network as a biomarker: a novel network-based sparse bayesian machine for pathway- driven drug response prediction,” Genes, vol. 10, no. 8,p. 602, 2019.
N. Kureshi, S. S. R. Abidi, and C. Blouin, “A predictive model for personalized therapeutic interventions in non- small cell lung cancer,” IEEE Journal of Biomedical and Health Informat- ics, vol. 20, no. 1, pp. 424–431, 2016.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Ishaan Batish (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
